Recombinant Human GTPase HRAS Protein

重组人GTPase HRAS蛋白 | 重组人类 GTPase HRAS 蛋白

c-H-ras | EC 3.6.5.2 | Ha-Ras | H-Ras-1 | p21ras | Transforming protein p21 | c-H-ras | CBAS/HAS | CHARAS1 | cHras | CTLO | GTPase HRas | H-Ras-1 | Ha-Ras | HAMSV | HaRas | HRAS | HRas1 | HRASIDX | KRAS | N-terminally processed | NRAS | p21ras | RASH_HUMA

rp170121-1mg

1mg

无载体

≥95%(SDS-PAGE)

>95% (SDS-PAGE)

Purity: >95%, by SDS-PAGE visualized with Coomassie® Blue Staining. Description： HRas, also known as HRAS, belongs to the small GTPase superfamily, Ras family, and is widely expressed. It functions in signal transduction pathways. HRas can bind GTP and GDP, and they have intrinsic GTPase activity. It undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Defects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS). FCSS is a rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities, tumor predisposition, skin, and musculoskeletal abnormalities. Defects in HRAS also can cause congenital myopathy with excess of muscle spindles. HRAS deficiency may be a cause of susceptibility to Hurthle cell thyroid carcinoma. It has been shown that defects in HRAS can cause susceptibility to bladder cancer which is a malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. Defects in HRAS are the cause of oral squamous cell carcinoma.

重组表达

21.8 kDa

N-His

22.4 kDa, under reducing conditions

E. coli Accession #: P01112 | E. coli

人(Human)

2-186 aa

MHHHHHHTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHQYREQIKRVKDSDDVPMVLVGNKCDLAARTVESRQAQDLARSYGIPYIETSAKTRQGVEDAFYTLVREIRQHKLRKLNPPDESGPGCMSCKC

No

Yes